Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.60 |
| ▸ | CA1 | P00915 | 12/20 | 0.60 |
| ▸ | CA9 | Q16790 | 10/20 | 0.60 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23705148 | 1.00 | CA2 (0.60) | CA2CA1CA9LGALS3ALDH1A1 | |
| SCHEMBL21191298 | 0.85 | CA1 (0.55) | CA2CA1CA9 | |
| SCHEMBL30524947 | 0.85 | HK2 (0.46) | CA2CA1CA9LGALS3 | |
| SCHEMBL24769405 | 0.85 | HK2 (0.46) | CA2CA1CA9LGALS3 | |
| SCHEMBL19477830 | 0.78 | CA2 (0.52) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL3316874 | 0.76 | LGALS3 (0.48) | CA2CA1CA9LGALS3 | |
| SCHEMBL3316869 | 0.76 | LGALS3 (0.48) | CA2CA1CA9LGALS3 | |
| SCHEMBL15310694 | 0.76 | CA9 (0.56) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL4787669 | 0.76 | LGALS3 (0.48) | CA2CA1CA9LGALS3 | |
| SCHEMBL3316862 | 0.76 | LGALS3 (0.48) | CA2CA1CA9LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | CA2 4417/4885CA1 4078/4885CA9 4030/4885 |
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | CA2 4350/4885CA1 3980/4885CA9 3806/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | CA2 4006/4885CA1 3524/4885CA9 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.